ArticleScientific reports2024
Association of platelet-to-lymphocyte ratio with 1-year all-cause mortality in ICU patients with heart failure.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic value of 9 immune-inflammatory markers for patients with dilated cardiomyopathy: A retrospective study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Association between platelet-to-lymphocyte ratio and 28-day all-cause mortality in patients with asymptomatic coronary artery disease: a cohort study.European journal of medical research · 2025Article
- Exploring the Platelet-to-Lymphocyte Ratio for Risk Stratification in Heart Failure: A Systematic Review.Cureus · 2025Review
- Relationship between the platelet-to-lymphocyte ratio and in-hospital mortality of ischemic stroke patients in the intensive care unit.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Platelet-to-Lymphocyte Ratio (PLR) has emerged as a cost-effective biomarker for systemic inflammation and adverse cardiovascular outcomes, yet its prognostic value in critically ill patients with heart failure (HF) remains unclear. Leveraging the MIMIC-IV database, this study investigates the association between PLR and 1-year all-cause mortality in 7,217 ICU patients with HF. Patients were stratified into tertiles (0-126.45, 126.45-252.40, and 252.40-1000), and mortality risk was analyzed using Kaplan-Meier survival curves and Cox proportional hazards models. Elevated PLR was independently associated with higher mortality, with the highest tertile showing a 36% increased risk compared to the lowest (HR 1.36, 95% CI: 1.23-1.50, P < 0.001). Each tertile increment corresponded to a 17% rise in risk. Subgroup analyses revealed stronger associations in hypertensive patients and identified renal dysfunction and red cell distribution width as key modifiers. Integrating PLR with SOFA and APS III scores significantly enhanced predictive accuracy. By reflecting systemic inflammation and immune dysregulation, PLR offers a robust tool for long-term risk stratification and personalized management of ICU patients with HF. These findings highlight the potential of PLR to refine prognostic models, guide clinical decision-making, and improve critical care outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.